Mylan, J&J Unit Reach Deal In Birth Control Drug Patent Row

Law360, New York (November 8, 2012, 5:15 PM EST) -- Mylan Inc. said Thursday that it had settled patent-infringement litigation launched by a Johnson & Johnson unit that will allow Mylan to sell a generic version of birth control drug Ortho Tri-Cyclen Lo starting Dec. 31, 2015.

The settlement ends Janssen Pharmaceuticals Inc.'s suit accusing Mylan and Indian generics maker Famy Care Ltd. — Mylan’s partner in marketing a generic version of Ortho Tri-Cyclen Lo in the U.S. — of filing abbreviated new drug applications with the U.S. Food and Drug Administration to produce and sell...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.